Keywords: Cubist Pharma, Adynxx, Optionto acquire, AYX1, Chronic pain
Cubist gains exclusive option to acquire Adynxx
Article | 26 February 2013
US drugmaker Cubist Pharmaceuticals (Nasdaq: CBST) has entered into an option agreement with privately-held, clinical-stage pharma company Adynxx, under which ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
